Emerald Mutual Fund Advisers Trust Boosts Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Mutual Fund Advisers Trust boosted its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 16.3% in the second quarter, Holdings Channel.com reports. The fund owned 836,541 shares of the medical technology company’s stock after buying an additional 117,217 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Alphatec were worth $8,742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. First Light Asset Management LLC grew its position in shares of Alphatec by 97.0% during the fourth quarter. First Light Asset Management LLC now owns 5,976,851 shares of the medical technology company’s stock worth $90,310,000 after acquiring an additional 2,943,310 shares during the last quarter. Artisan Partners Limited Partnership purchased a new position in Alphatec during the 4th quarter worth $19,050,000. Goldman Sachs Group Inc. increased its stake in Alphatec by 93.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,451,499 shares of the medical technology company’s stock valued at $21,932,000 after purchasing an additional 702,950 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Alphatec by 48.1% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,125,042 shares of the medical technology company’s stock valued at $29,305,000 after buying an additional 690,022 shares during the last quarter. Finally, Intrinsic Edge Capital Management LLC raised its holdings in shares of Alphatec by 72.2% in the fourth quarter. Intrinsic Edge Capital Management LLC now owns 1,599,849 shares of the medical technology company’s stock valued at $24,174,000 after buying an additional 670,788 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ATEC. Piper Sandler lowered their price target on Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Thursday, August 1st. Needham & Company LLC cut their price target on Alphatec from $23.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, August 22nd. Lake Street Capital decreased their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Alphatec Price Performance

Alphatec stock opened at $6.42 on Friday. The company has a market cap of $897.36 million, a P/E ratio of -4.31 and a beta of 1.40. Alphatec Holdings, Inc. has a one year low of $5.57 and a one year high of $17.34. The business has a fifty day moving average of $8.34 and a two-hundred day moving average of $10.89. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.21 and a current ratio of 2.22.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.03). The company had revenue of $145.57 million during the quarter, compared to analysts’ expectations of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The business’s revenue for the quarter was up 24.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.43) EPS. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Activity

In other Alphatec news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total transaction of $546,524.16. Following the sale, the general counsel now directly owns 245,638 shares in the company, valued at $2,672,541.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Alphatec news, Director David M. Demski purchased 50,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were acquired at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the completion of the transaction, the director now directly owns 288,441 shares of the company’s stock, valued at $1,635,460.47. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Tyson Eliot Marshall sold 50,232 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total transaction of $546,524.16. Following the transaction, the general counsel now directly owns 245,638 shares of the company’s stock, valued at $2,672,541.44. The disclosure for this sale can be found here. Insiders own 22.80% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.